Bicycle Therapeutics Plc - ADR

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

Bicycle Therapeutics: Early Stage Platform Technology Play With Multiple Upside Drivers

Bicycle Therapeutics: A Disruptive New Entrant To The Vast Targeted Cancer Treatment Space

Bicycle peptides are fully synthetic short peptides constrained to form two loops using a chemical connector compound known as a scaffold, which stabilizes their structural geometry.

Bicycle Therapeutics: Novel Bicycle Peptide Technology Could Disrupt The Monoclonal Antibodies Market

Shares of Bicycle Therapeutics PLC, which debuted on Wall Street in May, traded higher on Monday morning.

Bicycle Therapeutics Trades Higher On Positive Early-Stage Trial Results For Diabetic Macular Edema Therapy

Bicycle Therapeutics Ltd. shares  soared 29% in premarket trade Monday, after the company announced positive results in a trial of a treatment for diabetic macular edema, or DME, a disease that causes damage in the blood vessels of the retina that can harm vision.

Bicycle Therapeutics shares soar 29% premarket on news of positive trial of DME treatment

News for Bicycle Therapeutics Plc - ADR Stock (BCYC)